ProCE Banner Series

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

Experts review and give insights on the latest advances in histology-agnostic biomarkers and approved targeted therapies in this 1-hour CME/CE-certified workshop series. Register now!

  ACPE
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for physicians, nurse practitioners, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with malignant solid tumors.

All Events

Past Events

August

19

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

9:00 AM - 10:00 PM Eastern Time (ET)

In-person

Private Event | Host Group at Hilton, Daytona Beach, Florida

August

29

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team [Open Registration]

8:30 AM - 9:30 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group VT, Bennington, Vermont

August

31

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

11:00 AM - 12:00 PM Mountain Time (MT)

Virtual

Private Event | Host Group CO, Colorado Springs, Colorado

September

05

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event | Virtual Group MI, Royal Oak, Michigan

September

09

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

6:30 PM - 7:30 PM Pacific Time (PT)

In-person

Private Event | Host Group LA, Los Angeles, California

September

11

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group AL, Mobile, Alabama

September

16

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

8:30 AM - 9:30 AM Central Time (CT)

In-person

Private Event | Host Group at III, Houston, Texas

September

20

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group TX, Dallas, Texas

October

06

2023

Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

10:45 AM - 11:45 AM Central Time (CT)

Virtual

Private Event | Virtual Group OK, Norman, Oklahoma

Faculty

ProCE Banner Faculty
Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

ProCE Banner Faculty
Razelle Kurzrock, MD

Professor
Medical College of Wisconsin
Milwaukee, Wisconsin

ProCE Banner Faculty
Meredith McKean, MD, MPH

Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee 

ProCE Banner Faculty
Justin Moyers, MD

Medical Oncologist
The Angeles Clinic and Research Institute
Los Angeles, California 

ProCE Banner Faculty
Cesar A. Perez Batista, MD

Associate Professor of Medicine 
Department of Medicine 
University of Central Florida 
Director of Drug Development 
Sarah Cannon Research Institute at Florida Cancer Specialists 
Lake Nona Drug Development Unit
Orlando, Florida 

ProCE Banner Faculty
Vivek Subbiah, MD

Chief, Early-Phase Drug Development
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee

ProCE Banner Faculty
Tian Zhang, MD, MHS

Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Topics

  • Welcome and Introduction
  • Histology-Agnostic Biomarkers and Approved Targeted Therapies
    • BRAFV600E
    • Microsatellite instability-high/mismatch repair deficient
    • Tumor mutational burden-high
    • NTRK fusion
    • RET alterations
  • Investigational Histology-Agnostic Targets
  • Putting It All Together: Optimal Collaboration With the Multidisciplinary Team
  • Audience Question and Answer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncologists, pathologists, molecular pathologists, oncology physician associates/physician assistants, oncology nurses, pharmacists, and other healthcare professionals to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer.

Target Audience
This program is intended for physicians, nurse practitioners, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with malignant solid tumors.

Learning Objectives

  • Order appropriate assays or molecular tests to detect BRAF V600E, microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR), tumor mutation burden-high (TMB-H), and oncogenic gene fusions in patients with malignant solid tumors
  • Appraise emerging clinical efficacy and safety data supporting the use of multi-tumor and histology-agnostic therapies in solid tumors
  • Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence as well as expert and guideline recommendations
  • Develop strategies for managing immune-related adverse events associated with histology-agnostic treatment with immune checkpoint inhibitors
  • Identify and refer eligible patients with appropriate biomarkers for enrollment in ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-097-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Elevation Oncology, Merck Sharp & Dohme Corp., and Merus NV.